Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming SITC Annual Meeting Thumbnail Image Read more about Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming SITC Annual Meeting
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting Thumbnail Image Read more about Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting
Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at SITC Annual Meeting Thumbnail Image Read more about Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at SITC Annual Meeting
Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at 2021 SITC Annual Meeting Thumbnail Image Read more about Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at 2021 SITC Annual Meeting
NexImmune to Present at 2021 SITC Annual Meeting Thumbnail Image Read more about NexImmune to Present at 2021 SITC Annual Meeting
CARISMA Announces Multiple Abstracts Accepted for Presentation at 2021 SITC Annual Meeting Thumbnail Image Read more about CARISMA Announces Multiple Abstracts Accepted for Presentation at 2021 SITC Annual Meeting
BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies Thumbnail Image Read more about BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies
Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients With Advanced Solid Tumors Thumbnail Image Read more about Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients With Advanced Solid Tumors
Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China Thumbnail Image Read more about Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome Thumbnail Image Read more about X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
